Clinical features of hepatitis B virus-related hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 16, Issue 20, 2010, Pages 2463-2467

  Ishikawa, Toru ^a  

^a Saiseikai Niigata Second Hospital   (Japan)

Author keywords

Hepatitis B virus; Hepatocellular carcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; INTERFERON; LACTATE DEHYDROGENASE; LAMIVUDINE; VIRUS DNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CHRONIC LIVER DISEASE; CLINICAL FEATURE; ERADICATION THERAPY; GROWTH INHIBITION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER SURGERY; PORTAL VEIN THROMBOSIS; PROGNOSIS; SEQUENCE ANALYSIS; VIRUS CARCINOGENESIS; VIRUS LOAD; VIRUS REPLICATION;

EID: 77953266205     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i20.2463     Document Type: Article

References (25)

1. Ishikawa T, Ichida T, Yamagiwa S, Sugahara S, Uehara K, Okoshi S, Asakura H. High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J Gastroenterol Hepatol 2001; 16: 1274-1281
2. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Fu-kuda M, Koida I, Arase Y, Chayama K, Murashima N, Ku-mada H. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 1998; 82: 827-835
3. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531
4. Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, Okita K, Hayashi N, Okanoue T, Iino S, Tani-kawa K. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 2005; 32: 173-184
5. Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and postmortem tissue specimens. N Engl J Med 1981; 305: 1067-1073
6. Wang J, Chenivesse X, Henglein B, Bréchot C. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 1990; 343: 555-557
7. Lin CL, Chen JD, Liu CJ, Lee PH, Chen PJ, Lai MY, Kao JH, Chen DS. Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma. J Viral Hepat 2007; 14: 64-69
8. Orito E, Sugauchi F, Tanaka Y, Ichida T, Sata M, Tanaka E, Okanoue T, Sakugawa H, Watanabe H, Miyakawa H, Nishi-guchi S, Kumada H, Ueda R, Mizokami M. Differences of hepatocellular carcinoma patients with hepatitis B virus genotypes of Ba, Bj or C in Japan. Intervirology 2005; 48: 239-245
9. Tanizaki H, Ryu M, Kinoshita T, Kawano N, Konishi M, Cho A, Nakatsura T, Natsume T, Takahashi S, Sugita M, Izuishi K, Yoshino M, Furuse J, Iwasaki M, Tsubono Y. Comparison of clinical features and survival in patients with hepatitis B and C virus-related hepatocellular carcinoma. Jpn J Clin Oncol 1997; 27: 67-70
10. Tanabe G, Nuruki K, Baba Y, Imamura Y, Miyazono N, Ueno K, Arima T, Nakajyou M, Aikou T. A comparison of hepatocellular carcinoma associated with HBV or HCV infection. Hepatogastroenterology 1999; 46: 2442-2446
11. Okuda H, Obata H, Motoike Y, Hisamitsu T. Clinicopatho-logical features of hepatocellular carcinoma--comparison of hepatitis B seropositive and seronegative patients. Hepatogastroenterology 1984; 31: 64-68
12. Shijo H, Okazaki M, Koganemaru F, Higashi M, Sakaguchi S, Okumura M. Influence of hepatitis B virus infection and age on mode of growth of hepatocellular carcinoma. Cancer 1991; 67: 2626-2632
13. Ishikawa T, Imai M, Kamimura H, Tsuchiya A, Togashi T, Watanabe K, Seki K, Ohta H, Yoshida T, Kamimura T. Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. World J Gastroenterol 2007; 13: 5465-5470
14. Kubo S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Yamamoto T, Ikebe T, Wakasa K, Nishiguchi S, Kinoshita H. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer 2000; 88: 1016-1024
15. Nagasue N, Ono T, Yamanoi A, Kohno H, El-Assal ON, Taniura H, Uchida M. Prognostic factors and survival after hepatic resection for hepatocellular carcinoma without cirrhosis. Br J Surg 2001; 88: 515-522
16. Roayaie S, Haim MB, Emre S, Fishbein TM, Sheiner PA, Miller CM, Schwartz ME. Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience. Ann Surg Oncol 2000; 7: 764-770
17. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, Hamamura K, Imai Y, Yoshida H, Shiina S, Omata M. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology 2000; 32: 1216-1223
18. Kubo S, Hirohashi K, Yamazaki O, Matsuyama M, Tanaka H, Horii K, Shuto T, Yamamoto T, Kawai S, Wakasa K, Nishiguchi S, Kinoshita H. Effect of the presence of hepatitis B e antigen on prognosis after liver resection for hepatocellular carcinoma in patients with chronic hepatitis B. World J Surg 2002; 26: 555-560
19. Jang JW, Choi JY, Bae SH, Yoon SK, Woo HY, Chang UI, Kim CW, Nam SW, Cho SH, Yang JM, Lee CD. The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive trans-arterial chemolipiodolization: implications for viral suppression to reduce the risk of cancer recurrence. Cancer 2007; 110: 1760-1767
20. Kubo S, Tanaka H, Takemura S, Yamamoto S, Hai S, Ichikawa T, Kodai S, Shinkawa H, Sakaguchi H, Tamori A, Habu Nishiguchi S. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res 2007; 37: 94-100
21. Kuzuya T, Katano Y, Kumada T, Toyoda H, Nakano I, Hi-rooka Y, Itoh A, Ishigami M, Hayashi K, Honda T, Goto H. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 2007; 22: 1929-1935
22. Ishikawa T. Secondary prevention of recurrence by inter-feron therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. World J Gastroenterol 2008; 14: 6140-6144
23. Someya T, Ikeda K, Saitoh S, Kobayashi M, Hosaka T, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H. Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis. J Gastroenterol 2006; 41: 1206-1213
24. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J, Zhou XD, Zhou J, Qiu SJ, Shen YF. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006; 132: 458-465
25. Mutimer D, Naoumov N, Honkoop P, Marinos G, Ahmed M, de Man R, McPhillips P, Johnson M, Williams R, Elias Schalm S. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol 1998; 28: 923-929